BioMark Diagnostics Inc. develops liquid biopsy technologies for early cancer detection, with news centered on metabolomic profiling, machine learning models, and lung cancer screening applications. Company updates commonly cover clinical research collaborations, peer-reviewed validation work, respiratory medicine forums, and efforts to apply biomarker testing alongside established screening pathways.
BioMark news also includes intellectual property developments for its metabolic liquid biopsy platform, recognition of collaborative lung cancer screening projects, governance appointments, and commercialization-related activity tied to laboratory standards, distribution channels, and market access for oncology diagnostics.
Summary not available.
Summary not available.
Summary not available.